Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 275
A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program Acronyms AACI Association of American Cancer Institutes AAMC American Association of Medical Colleges ACOSOG American College of Surgeons Oncology Group ACRIN American College of Radiology Imaging Network ACS CAN American Cancer Society Cancer Action Network AE adverse event AHRQ Agency for Healthcare Research and Quality AIPC androgen-independent prostate cancer ALERT Act 21st Century Cancer Access to Life-Saving Early Detection, Research, and Treatment Act ALL acute lymphoblastic leukemia AML acute myeloid leukemia ARRA American Recovery and Reinvestment Act of 2009 ASCO American Society of Clinical Oncology BCG bacillus Calmette-Guérin BICR blinded independent central review BIG Breast International Group BRB Biometric Research Branch BSA Board of Scientific Advisors (National Cancer Institute) CALGB Cancer and Leukemia Group B CCG Children’s Cancer Group CCOP Community Clinical Oncology Program CCSG Cancer Center Support Grant
OCR for page 276
A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program CER comparative effectiveness research CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone CIRB central institutional review board CLL chronic lymphocytic leukemia CMS Centers for Medicare & Medicaid Services COG Children’s Oncology Group CRADA Cooperative Research and Development Agreement CRI Clinical Research Initiative (Association of American Cancer Institutes) CSDD Center for the Study of Drug Development CT computed tomography CTAC Clinical Trials Advisory Committee CTEP Cancer Therapy Evaluation Program CTMB Clinical Trials Monitoring Branch CTROC Clinical Trials and Translational Research Operations Committee CTSA Clinical and Translational Science Awards CTSU Cancer Trials Support Unit CTTI Clinical Trials Transformation Initiative CTU Clinical Trials Unit CTWG Clinical Trials Working Group CYP2D6 cytochrome P-450 2D6 DCE-MRI dynamic contrast-enhanced magnetic resonance imaging DCPC Division of Cancer Prevention and Control DCTD Division of Cancer Treatment and Diagnosis DCTDC Division of Cancer Treatment, Diagnosis, and Centers ECOG Eastern Cooperative Oncology Group EGFR epidermal growth factor receptor EMR electronic medical record EORTC European Organisation for Research and Treatment of Cancer ER estrogen receptor ERISA Employee Retirement Income Security Act of 1974 5-FU fluorouracil 18F-FDG fluorine-18 fluorodeoxyglucose FDA Food and Drug Administration FDAAA Food and Drug Administration Amendments Act of 2007 FNIH Foundation for the National Institutes of Health FOLFOX4 oxaliplatin, 5-fluorouracil, and leucovorin
OCR for page 277
A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program FTE full-time equivalent GIST gastrointestinal stromal tumors GOG Gynecologic Oncology Group HER-2 human epidermal growth factor receptor 2 HHS U.S. Department of Health and Human Services HIPAA Health Insurance Portability and Accountability Act ICF informed-consent form IDB Investigational Drug Branch IDE investigational device exemption IND investigational new drug IOM Institute of Medicine IP intellectual property IRB institutional review board I-SPY TRIAL Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And moLecular analysis KRAS Kirsten ras LOI letter of intent MAMS multiarm, multistage (trial design) MARVEL Marker Validation for Erlotinib in Lung cancer MINDACT Microarray in Node-negative Disease may Avoid ChemoTherapy MMRC Multiple Myeloma Research Consortium MRC Medical Research Council MRD minimal residual disease MRI magnetic resonance imaging NBL neuroblastoma NCAB National Cancer Advisory Board NCCF National Children’s Cancer Foundation NCCN National Comprehensive Cancer Network NCCTG North Central Cancer Treatment Group NCD National Coverage Decision NCI National Cancer Institute NIH National Institutes of Health NNCO National Nanotechnology Coordination Office NSABP National Surgical Adjuvant Breast and Bowel Project NSCLC non-small-cell lung cancer
OCR for page 278
A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program NSET Nanoscale Science, Engineering, and Technology Subcommittee OCR Office for Civil Rights (U.S. Department of Health and Human Services) OEWG Operational Efficiency Working Group OHRP Office for Human Research Protections (U.S. Department of Health and Human Services) pCR pathologic complete response PERCIST PET Response Criteria in Solid Tumors PET positron emission tomography Ph+ Philadelphia chromosome positive POG Pediatric Oncology Group QIBA Quantitative Imaging Biomarkers Alliance QOPI Quality Oncology Practice Initiative RECIST Response Evaluation Criteria in Solid Tumors RTOG Radiation Therapy Oncology Group SACHRP Secretary’s Advisory Committee on Human Research Protections SPECT single-photon emission computed tomography SPORE Specialized Programs of Research Excellence STAMPEDE Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy STPI Science and Technology Policy Institute SWOG Southwest Oncology Group TAILORx Trial Assigning IndividuaLized Options for Treatment TRWG Translational Research Working Group Tufts CSDD Tufts Center for the Study of Drug Development US ultrasound VA U.S. Department of Veterans Affairs VEGF vascular endothelial growth factor